levofloxacin has been researched along with emetine in 3 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (emetine) | Trials (emetine) | Recent Studies (post-2010) (emetine) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,797 | 24 | 162 |
| Protein | Taxonomy | levofloxacin (IC50) | emetine (IC50) |
|---|---|---|---|
| Glucose transporter | Leishmania mexicana | 0.081 | |
| Serine hydrolase RBBP9 | Homo sapiens (human) | 7.8 | |
| Hexose transporter 1 | Plasmodium falciparum (malaria parasite P. falciparum) | 0.09 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 7.0667 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.038 | |
| Solute carrier family 2, facilitated glucose transporter member 1 | Homo sapiens (human) | 0.108 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.182 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.0965 | |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | 0.0965 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
3 other study(ies) available for levofloxacin and emetine
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |